Drug intelligence / Profile preview

recombinant collagen

Development stage: Unknown
Lead developer: FibroGen
Modality: Recombinant Proteins and Enzymes
Administration: Intradermal, Topical, Implantation

Overview

Recombinant collagen is a biotechnologically produced form of collagen, used in various biomedical applications, including tissue engineering, drug delivery systems, and cosmetic medicine. It is produced through recombinant DNA technology, allowing for the creation of collagen without the risks associated with animal-derived sources. Recombinant collagen can be used as a skin booster, injected intradermally to enhance skin quality, and in wound healing and orthopedic applications.

Brand names: SkinColla
Other names: recombinant human collagenrecombinant humanized collagen

Beyond the preview

Go deeper on recombinant collagen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant collagen.

Explore the full profile